Charles River Laboratories has signed a marketing and distribution agreement with Pfizer to provide certain Pfizer-developed genetically modified research models to the global biomedical research community. Under this agreement, CRL will supply a number of pre-competitive, transgenic research models developed by Pfizer across a broad range of therapeutic areas, including neuroscience, diabetes and cardiovascular disease.

“The use of genetically modified research models continues to emerge as an important tool to allow scientists in their research to target specific disease states and genetic markers,” said Dr. Iva Morse, corporate vice president, global research model services at Charles River.

Rick Connell, vice president and worldwide head of the external research solutions center of excellence at Pfizer, said, “This agreement with Charles River aligns with Pfizer’s strategy to externalize our pre-competitive tools and assets to a broader community of scientists outside of Pfizer’s walls. We collectively share an interest in seeing science advance to enable the continued development of innovative medicines for patients.”